

Supplemental Table 1 – Comparison between studied groups in a per-patient analysis.

| Parameter | Romanian group (n=5095) | Hungarian minority (n=1417) | Roma minority (n=355) | p value |
|----------------------------------|----------------------------|--------------------------------|--------------------------|---------|
| Male sex | 3611 (70.87%) | 901 (63.59%) | 250 (70.42%) | <0.0001 |
| Age (years) | 64.87 ± 10.52 | 65.08 ± 11.08 | 58.14 ± 11.33 | <0.0001 |
| BMI (kg/m ²) | 28.93 ± 4.61 | 28.54 ± 4.49 | 29.84 ± 6.04 | 0.001 |
| Hypertension | 2524 (49.54%) | 660 (46.58%) | 162 (45.63%) | 0.06 |
| Hypercholesterolemia | 1944 (38.16%) | 535 (37.76%) | 124 (34.93%) | 0.47 |
| Smoking status | 2182 (42.83%) | 584 (41.21%) | 215 (60.56%) | <0.0001 |
| Diabetes mellitus | 950 (18.65%) | 230 (16.23%) | 76 (21.41%) | 0.03 |
| Prior MI | 968 (19.00%) | 245 (17.29%) | 65 (18.31%) | 0.33 |
| Prior CABG | 148 (2.90%) | 24 (1.69%) | 7 (1.97%) | 0.03 |
| Prior PCI | 1047 (20.55%) | 287 (20.25%) | 57 (16.06%) | 0.12 |
| COPD | 453 (8.89%) | 131 (9.24%) | 43 (12.11%) | 0.12 |
| Atrial fibrillation | 628 (12.33%) | 190 (13.41%) | 30 (8.45%) | 0.03 |
| ACS-STE | 1519 (29.81%) | 454 (32.04%) | 173 (48.73%) | <0.0001 |
| ACS-NSTEMI | 449 (8.81%) | 139 (9.81%) | 50 (14.08%) | 0.003 |
| ACS-UA | 906 (17.78%) | 260 (18.35%) | 47 (13.24%) | 0.07 |
| CCS | 2221 (43.59%) | 564 (39.80%) | 85 (23.94%) | <0.0001 |
| Creatinine (mg/dL) | 1.08 ± 0.75 | 1.03 ± 0.59 | 1.09 ± 0.77 | 0.07 |
| CrCl <45 mL/min | 180 (3.53%) | 39 (2.75%) | 16 (4.51%) | 0.18 |
| Hemoglobin (g/dL) | 13.64 ± 1.71 | 13.71 ± 1.74 | 13.96 ± 1.84 | 0.002 |
| Platelets (×10 ³ /µL) | 235.84 ± 71.71 | 238.15 ± 83.79 | 250.34 ± 72.73 | 0.002 |
| WBC (×10 ³ /µL) | 9.2 ± 3.63 | 9.34 ± 4.02 | 10.69 ± 4.33 | <0.0001 |
| LDL-cholesterol (mg/dL) | 108.53 ± 42.43 | 108.96 ± 44.63 | 120.29 ± 45.4 | <0.0001 |
| HDL-cholesterol (mg/dL) | 37.06 ± 10.44 | 37.55 ± 9.93 | 34.88 ± 9.76 | 0.0002 |
| Triglyceride (mg/dL) | 150.98 ± 105.64 | 157.15 ± 112.3 | 203.8 ± 171.3 | <0.0001 |
| Total cholesterol (mg/dL) | 175.07 ± 49.32 | 177.61 ± 53.55 | 191.92 ± 53.93 | <0.0001 |
| LVEF (%) | 46.55 ± 9.86 | 46.56 ± 10.2 | 43.76 ± 9.64 | <0.0001 |
| LVEF<40% | 823 (16.15%) | 232 (16.37%) | 80 (22.54%) | 0.007 |
| LVEF =41-49% | 2199 (43.16%) | 627 (44.25%) | 120 (33.80%) | 0.001 |
| LVEF ≥50% | 1510 (29.64%) | 446 (31.47%) | 135 (38.03%) | 0.002 |
| Killip class ≥4 | 80 (1.57%) | 23 (1.62%) | 8 (2.25%) | 0.61 |
| ICU stay | 300 (5.89%) | 83 (5.86%) | 17 (4.79%) | 0.69 |
| TIMI pre-PCI ≤1 | 1.66 ± 1.37 | 1.63 ± 1.36 | 1.42 ± 1.37 | 0.01 |
| Number of diseased vessels | 2.02 ± 0.83 | 2.03 ± 0.82 | 2.06 ± 0.79 | 0.75 |
| SYNTAX score | 17.65 ± 11.57 | 18.26 ± 11.9 | 16.66 ± 9.42 | 0.63 |
| SYNTAX II score | 14.79 ± 12.60 | 16.12 ± 14.57 | 13.27 ± 12.19 | 0.03 |
| LM angioplasty | 304 (5.97%) | 83 (5.86%) | 15 (4.23%) | 0.40 |

| | | | | |
|------------------------------|------------------|-------------------|-------------------|-------|
| LAD angioplasty | 2417 (47.44%) | 686 (48.41%) | 174 (49.01%) | 0.71 |
| CXA angioplasty | 1289 (25.30%) | 363 (25.62%) | 82 (23.10%) | 0.61 |
| RCA angioplasty | 1609 (31.58%) | 441 (31.12%) | 117 (32.96%) | 0.79 |
| Proximal segment angioplasty | 2315 (45.44%) | 659 (46.51%) | 163 (45.92%) | 0.77 |
| Complete revascularization | 2031 (39.86%) | 526 (37.12%) | 119 (33.52%) | 0.01 |
| Maximum stent diameter | 3.66 ± 9.96 | 4.33 ± 16.79 | 3.4 ± 2.56 | 0.21 |
| Total stent length | 31.72 ± 19.28 | 30.46 ± 17.98 | 28.2 ± 14.87 | 0.003 |
| Number of stents | 1.54 ± 0.89 | 1.51 ± 0.83 | 1.38 ± 0.73 | 0.006 |
| Segments treated | 1.38 ± 0.74 | 1.36 ± 0.68 | 1.27 ± 0.61 | 0.02 |
| TIMI post-PCI ≤2 | 2.9 ± 0.46 | 2.89 ± 0.51 | 2.9 ± 0.45 | 0.82 |
| Hospitalization cost (€) | 1969.24 ± 2729.9 | 1931.26 ± 2819.82 | 1614.53 ± 1266.47 | 0.06 |

ACS – acute coronary syndrome; BMI – body mass index; CABG – coronary artery bypass graft; CCS – chronic coronary syndrome; CrCl – creatinine clearance; COPD – chronic obstructive pulmonary disease; CXA – circumflex artery; HDL – high density lipoprotein; HR – hazard ratio; ICU – intensive care unit; LAD – left anterior descending artery; LDL – low density lipoprotein; LM – left main artery; LVEF – left ventricular ejection fraction; MI – myocardial infarction; PCI – percutaneous coronary intervention; RCA – right coronary artery; TIMI – Thrombolysis In Myocardial Infarction; UA – unstable angina; WBC – white blood cells.

Supplemental Table 2 – Comparison between studied groups in a per-PCI analysis.

| Parameter | Romanian group (n=6238) | Hungarian minority (n=1780) | Roma minority (n=424) | p value |
|----------------------------------|----------------------------|--------------------------------|--------------------------|---------|
| Male sex | 4454 (71.40%) | 1146 (64.38%) | 295 (69.58%) | <0.0001 |
| Age (years) | 64.62 ± 10.34 | 65.19 ± 10.89 | 58.33 ± 11.08 | <0.0001 |
| BMI (kg/m ²) | 28.96 ± 4.65 | 28.65 ± 4.57 | 29.89 ± 5.98 | 0.0002 |
| Hypertension | 3268 (52.39%) | 908 (51.01%) | 216 (50.94%) | 0.53 |
| Hypercholesterolemia | 2548 (40.85%) | 719 (40.39%) | 164 (38.68%) | 0.66 |
| Smoking status | 2705 (43.36%) | 735 (41.29%) | 254 (59.91%) | <0.0001 |
| Diabetes mellitus | 1330 (21.32%) | 344 (19.33%) | 104 (24.53%) | 0.03 |
| Prior MI | 1331 (21.34%) | 361 (20.28%) | 93 (21.93%) | 0.57 |
| Prior CABG | 183 (2.93%) | 32 (1.80%) | 7 (1.65%) | 0.01 |
| Prior PCI | 1616 (25.91%) | 452 (25.39%) | 90 (21.23%) | 0.10 |
| COPD | 505 (8.10%) | 153 (8.60%) | 51 (12.03%) | 0.01 |
| Atrial fibrillation | 714 (11.45%) | 211 (11.85%) | 36 (8.49%) | 0.14 |
| ACS-STE | 1602 (25.68%) | 481 (27.02%) | 180 (42.45%) | <0.0001 |
| ACS-NSTEMI | 491 (7.87%) | 167 (9.38%) | 58 (13.68%) | 0.0001 |
| ACS-UA | 1135 (18.19%) | 339 (19.04%) | 64 (15.09%) | 0.16 |
| CCS | 3010 (48.25%) | 793 (44.55%) | 122 (28.77%) | <0.0001 |
| Creatinine (mg/dL) | 1.08 ± 0.78 | 1.03 ± 0.61 | 1.12 ± 0.81 | 0.02 |
| CrCl <45 mL/min | 217 (3.48%) | 57 (3.20%) | 20 (4.72%) | 0.31 |
| Hemoglobin (g/dL) | 13.6 ± 1.68 | 13.67 ± 1.7 | 13.87 ± 1.85 | 0.006 |
| Platelets (×10 ³ /µL) | 303.18 ± 567.86 | 118.37 ± 124.47 | 248.4 (77.62-578.02) | 0.08 |
| WBC (×10 ³ /µL) | 235.55 ± 70.42 | 236.23 ± 80.26 | 249.66 ± 74.21 | 0.0008 |
| LDL-cholesterol (mg/dL) | 8.99 ± 3.51 | 9.04 ± 3.8 | 10.44 ± 4.23 | <0.0001 |
| HDL-cholesterol (mg/dL) | 105.38 ± 42.06 | 106.03 ± 44.5 | 116.98 ± 46.56 | <0.0001 |
| Triglyceride (mg/dL) | 36.85 ± 10.33 | 37.24 ± 9.82 | 34.5 ± 9.4 | <0.0001 |
| Total cholesterol (mg/dL) | 151.42 ± 112.38 | 156.7 ± 108.92 | 207.21 ± 169.43 | <0.0001 |
| LVEF (%) | 47.02 ± 9.71 | 47.14 ± 10.06 | 44.16 ± 9.74 | <0.0001 |
| LVEF<40% | 943 (15.12%) | 270 (15.17%) | 91 (21.46%) | 0.002 |
| LVEF =41-49% | 1804 (28.92%) | 543 (30.51%) | 160 (37.74%) | 0.0004 |
| LVEF ≥50% | 2859 (45.83%) | 837 (47.02%) | 151 (35.61%) | 0.0001 |
| Killip class ≥4 | 84 (1.35%) | 23 (1.29%) | 8 (1.89%) | 0.62 |
| ICU stay | 314 (5.03%) | 89 (5.00%) | 19 (4.48%) | 0.88 |
| TIMI pre-PCI ≤1 | 1.7 ± 1.37 | 1.71 ± 1.35 | 1.47 ± 1.37 | 0.003 |
| Number of diseased vessels | 2.1 ± 0.82 | 2.12 ± 0.81 | 2.12 ± 0.78 | 0.69 |
| SYNTAX score | 18.63 ± 11.63 | 19.23 ± 11.75 | 17.06 ± 8.81 | 0.33 |
| SYNTAX II score | 14.12 ± 12.32 | 15.51 ± 14.47 | 13.01 ± 11.98 | 0.04 |
| LM angioplasty | 359 (5.76%) | 98 (5.51%) | 18 (4.25%) | 0.41 |

| | | | | |
|------------------------------|-------------------|-------------------|-------------------|--------|
| LAD angioplasty | 2889 (46.31%) | 828 (46.52%) | 198 (46.70%) | 0.97 |
| CXA angioplasty | 1612 (25.84%) | 478 (26.85%) | 109 (25.71%) | 0.68 |
| RCA angioplasty | 1997 (32.01%) | 559 (31.40%) | 139 (32.78%) | 0.82 |
| Proximal segment angioplasty | 2791 (44.74%) | 809 (45.45%) | 189 (44.58%) | 0.86 |
| Complete revascularization | 2331 (37.37%) | 614 (34.49%) | 131 (30.90%) | 0.004 |
| Maximum stent diameter | 3.75 ± 11.28 | 4.31 ± 16.72 | 3.34 ± 2.34 | 0.25 |
| Total stent length | 31.86 ± 19.31 | 30.18 ± 17.73 | 28.27 ± 14.72 | 0.0002 |
| Number of stents | 1.56 ± 0.9 | 1.53 ± 0.84 | 1.39 ± 0.73 | 0.001 |
| Segments treated | 1.4 ± 0.75 | 1.37 ± 0.68 | 1.28 ± 0.6 | 0.003 |
| TIMI post-PCI ≤2 | 2.91 ± 0.45 | 2.9 ± 0.48 | 2.91 ± 0.43 | 0.95 |
| Hospitalization cost (€) | 1883.63 ± 2534.63 | 1855.12 ± 2595.61 | 1604.08 ± 1484.18 | 0.04 |

ACS – acute coronary syndrome; BMI – body mass index; CABG – coronary artery bypass graft; CCS – chronic coronary syndrome; CrCl – creatinine clearance; COPD – chronic obstructive pulmonary disease; CXA – circumflex artery; HDL – high density lipoprotein; HR – hazard ratio; ICU – intensive care unit; LAD – left anterior descending artery; LDL – low density lipoprotein; LM – left main artery; LVEF – left ventricular ejection fraction; MI – myocardial infarction; PCI – percutaneous coronary intervention; RCA – right coronary artery; TIMI – Thrombolysis In Myocardial Infarction; UA – unstable angina; WBC – white blood cells.

Supplemental Table 3 – Extensive characteristics of the studied population.

| Parameter | All patients (n=6867) | All-cause death | P |
|--|------------------------|------------------|---------|
| Male sex | 4762 (69.35%) | 0.9 (0.8-1.0) | 0.05 |
| Age (years) | 64.56 ± 10.79 | 1.06 (1.05-1.07) | <0.0001 |
| BMI (kg/m ²) | 28.88 ± 4.74 | 1 (0.98-1.01) | 0.56 |
| Previous MI | 1278 (18.61%) | 1.03 (0.91-1.18) | 0.61 |
| Previous CABG | 179 (2.61%) | 0.99 (0.73-1.36) | 0.97 |
| Previous PCI | 1391 (20.26%) | 0.83 (0.73-0.95) | 0.007 |
| Stroke/TIA | 475 (6.92%) | 2.23 (1.83-2.68) | <0.0001 |
| Atrial fibrillation | 848 (12.35%) | 2.18 (1.92-2.48) | <0.0001 |
| Peripheral artery disease | 745 (10.85%) | 2.02 (1.77-2.38) | <0.0001 |
| Chronic kidney disease | 505 (7.35%) | 3.59 (3.01-4.25) | <0.0001 |
| Complete LBBB | 219 (3.19%) | 1.95 (1.45-2.55) | <0.0001 |
| Implantable device | 186 (2.71%) | 1.58 (1.15-2.21) | 0.002 |
| Valvular heart disease | 404 (5.88%) | 2.23 (1.8-2.62) | <0.0001 |
| Dilated cardiomyopathy | 581 (8.46%) | 1.96 (1.62-2.36) | <0.0001 |
| Chronic heart failure | 804 (11.71%) | 1.66 (1.42-1.95) | <0.0001 |
| COPD | 627 (9.13%) | 2.1 (1.82-2.43) | <0.0001 |
| Smoking status | 2981 (43.41%) | 1.26 (1.1-1.45) | 0.0009 |
| Diabetes Mellitus | 1256 (18.29%) | 1.44 (1.28-1.62) | <0.0001 |
| Arterial hypertension | 3346 (48.73%) | 1.03 (0.92-1.14) | 0.66 |
| Dyslipidaemia | 2603 (37.91%) | 0.84 (0.76-0.94) | 0.002 |
| LVEF (%) | 46.4 ± 9.94 | 0.94 (0.93-0.94) | <0.0001 |
| LVEF≤40% | 1135 (16.53%) | 3.24 (2.89-3.63) | <0.0001 |
| LVEF =41-49% | 2946 (42.9%) | 0.95 (0.85-1.07) | 0.39 |
| LVEF ≥50% | 2091 (30.45%) | 0.38 (0.34-0.43) | <0.0001 |
| NT-proBNP (pg/ml) | 939.11 (215.3-2872.87) | 2.96 (1.72-5.4) | 0.0008 |
| ACS-STE | 2146 (31.25%) | 1.81 (1.62-2.01) | <0.0001 |
| ACS-NSTE | 638 (9.29%) | 1.45 (1.23-1.71) | <0.0001 |
| UA | 1213 (17.66%) | 0.72 (0.62-0.84) | <0.0001 |
| CCS | 2870 (41.79%) | 0.62 (0.55-0.69) | <0.0001 |
| Heart rate (bpm) | 75.16 (66.39-84.69) | 1.6 (1.39-1.83) | <0.0001 |
| Systolic BP (mmHg) | 133.12 (120.56-149.58) | 1.11 (0.98-1.3) | 0.26 |
| Diastolic BP (mmHg) | 81.54 (70.2-88.51) | 0.94 (0.82-1.06) | 0.18 |
| Killip class | 1 (1.01-1.02) | 3.03 (2.11-4.18) | <0.0001 |
| Time from symptom onset to hospitalization (hours) * | 10.16 (5.32-21.82) | 1.18 (0.89-1.49) | 0.33 |
| Time from hospitalization to PCI (hours) | 25.05 (2.83-64.04) | 1.13 (1.02-1.31) | 0.05 |
| Time from symptom onset to PCI (hours) * | 17.46 (6.87-55.27) | 1.21 (0.94-1.51) | 0.25 |
| Right coronary dominance | 821 (11.96%) | 1.32 (1.11-1.54) | 0.004 |
| RCA lesion | 3925 (57.16%) | 1.43 (1.22-1.64) | <0.0001 |
| LAD lesion | 4837 (70.44%) | 1.29 (1.11-1.46) | 0.001 |
| CXA lesion | 3283 (47.81%) | 1.56 (1.44-1.77) | <0.0001 |
| LM lesion | 548 (7.98%) | 1.67 (1.36-2.1) | <0.0001 |
| RCA angioplasty | 2192 (31.92%) | 1.02 (0.92-1.14) | 0.61 |
| LAD angioplasty | 3185 (46.38%) | 1.04 (0.93-1.15) | 0.44 |
| CXA angioplasty | 1789 (26.05%) | 1.15 (1.02-1.29) | 0.01 |
| LM angioplasty | 394 (5.74%) | 1.61 (1.33-1.95) | 0.006 |
| Number of diseased coronaries | 2 (1.01-3.04) | 1.83 (1.63-2.13) | <0.0001 |
| Proximal segment angioplasty | 3058 (44.53%) | 1.44 (1.27-1.6) | <0.0001 |


| | | | |
|--|-----------------------|---------------------|---------|
| Number of segments treated | 1.01 (1.02-2.03) | 1.43 (1.26-1.66) | <0.0001 |
| PCI with 1 DES on one coronary | 4171 (60.74%) | 0.65 (0.6-0.76) | <0.0001 |
| PCI with at least 2 DES on one coronary | 1910 (27.81%) | 1.21 (1.03-1.37) | 0.03 |
| PCI with at least 2 DES on at least two coronaries | 543 (7.91%) | 1.8 (1.45-2.16) | <0.0001 |
| PCI with balloon on one coronary | 555 (8.08%) | 1.56 (1.29-1.94) | <0.0001 |
| PCI with balloon on at least two coronaries | 7 (0.1%) | 2.48 (0.63-10.09) | 0.21 |
| TIMI pre-PCI | 2.02 (0-3.02) | 0.81 (0.69-0.9) | <0.0001 |
| Complete revascularization | 2668 (38.85%) | 0.7 (0.61-0.8) | <0.0001 |
| Maximum stent diameter | 3.01 (2.78-3.55) | 1.03 (0.86-1.16) | 0.87 |
| Total stent length | 26.45 (18.1-38.58) | 1.34 (1.14-1.53) | 0.004 |
| Number of stents | 1.01 (1-2.03) | 1.59 (1.37-1.75) | <0.0001 |
| Resolute drug-eluting stent | 2951 (42.97%) | 0.92 (0.83-1.03) | 0.19 |
| Promus drug-eluting stent | 1220 (17.77%) | 0.95 (0.83-1.10) | 0.54 |
| Xience drug-eluting stent | 2106 (30.67%) | 1.03 (0.91-1.16) | 0.6 |
| Orsiro drug-eluting stent | 1387 (20.2%) | 1.47 (1.26-1.71) | <0.0001 |
| Ultimaster drug-eluting stent | 409 (5.96%) | 0.75 (0.58-0.97) | 0.03 |
| Contrast volume (ml) | 152.9 (130.63-203.99) | 1.41 (1.23-1.69) | <0.0001 |
| Eptifibatide | 724 (10.54%) | 0.93 (0.78-1.13) | 0.4 |
| Thrombectomy | 810 (11.8%) | 1.27 (1.01-1.47) | 0.05 |
| Pre-dilatation | 3845 (55.99%) | 1.42 (1.26-1.62) | <0.0001 |
| Post-dilatation | 4923 (71.69%) | 1.02 (0.91-1.14) | 1.03 |
| Adenosine | 215 (3.13%) | 0.76 (0.53-1.17) | 0.19 |
| Optical coherence tomography use | 202 (2.94%) | 0.76 (0.5-1.11) | 0.11 |
| Fractional flow reserve use | 197 (2.87%) | 0.43 (0.26-0.71) | 0.002 |
| Rotablation | 74 (1.08%) | 1.8 (1.17-2.94) | 0.01 |
| No-reflow | 164 (2.39%) | 1.65 (1.21-2.4) | 0.002 |
| Drug-eluting balloon | 74 (1.08%) | 1.3 (0.74-2.3) | 0.41 |
| Cutting balloon | 125 (1.82%) | 1.19 (0.79-1.8) | 0.49 |
| Intra-aortic balloon pump | 49 (0.71%) | 3.69 (2.27-5.88) | <0.0001 |
| Radial vascular access | 5452 (79.39%) | 0.75 (0.66-0.89) | <0.0001 |
| Vascular closure device | 439 (6.39%) | 1.78 (1.42-2.16) | <0.0001 |
| Temporary pacing | 53 (0.77%) | 2.42 (1.42-4.12) | 0.001 |
| Electrical cardioversion during PCI | 71 (1.03%) | 1.93 (1.21-3.23) | 0.01 |
| Cardiac arrest during PCI | 51 (0.74%) | 2.7 (1.56-4.81) | 0.006 |
| Cardiogenic shock | 70 (1.02%) | 2.96 (1.92-4.6) | <0.0001 |
| Intensive care unit stay | 400 (5.82%) | 11.61 (10.05-13.42) | <0.0001 |
| Mechanical ventilation | 257 (3.74%) | 3.06 (2.25-4.34) | <0.0001 |
| CPR during hospitalization | 42 (0.61%) | 2.32 (1.26-4.58) | 0.01 |
| Hospitalization days | 5.66 (3.97-7.5) | 1.82 (1.6-2.04) | <0.0001 |
| Beta-blocker | 6214 (90.5%) | 0.93 (0.76-1.08) | 0.21 |
| ACEI/ARB | 6269 (91.3%) | 0.85 (0.74-0.94) | 0.004 |
| Aldosterone receptor inhibitor | 2234 (32.53%) | 2.15 (1.89-2.4) | <0.0001 |
| Ticagrelor | 1905 (27.74%) | 0.51 (0.43-0.6) | <0.0001 |
| Clopidogrel | 4830 (70.3%) | 1.88 (1.6-2.21) | <0.0001 |
| Aspirin | 6509 (94.8%) | 0.52 (0.35-0.73) | 0.009 |
| Direct oral anticoagulant | 432 (6.2%) | 1.66 (1.33-2.17) | 0.009 |
| ARNI | 376 (19.24%) | 3.1 (1.87-4.89) | <0.0001 |
| Statin | 6674 (97.2%) | 0.62 (0.42-0.9) | 0.001 |
| SGLT2 inhibitors | 229 (11.72%) | 1.83 (1.04-3.2) | 0.06 |
| Fibrates | 385 (5.61%) | 0.78 (0.53-1.16) | 0.16 |
| Amiodarone | 604 (8.8%) | 1.97 (1.61-2.3) | <0.0001 |

| | | | |
|---|----------------|------------------|---------|
| Digitalis | 46 (0.67%) | 2.4 (1.47-3.93) | 0.002 |
| Vitamin K antagonists | 404 (5.8%) | 2.1 (1.78-2.55) | <0.0001 |
| Ivabradine | 307 (4.47%) | 2.02 (1.57-2.56) | <0.0001 |
| Creatinine (mg/dL) | 1.07 ± 0.72 | 1.31 (1.27-1.35) | <0.0001 |
| CrCl <45 mL/min | 235 (3.42%) | 3.74 (3.1-4.51) | <0.0001 |
| Hemoglobin (g/dL) | 13.67 ± 1.73 | 0.8 (0.77-0.82) | <0.0001 |
| Platelets ($\times 10^3/\mu\text{L}$) | 237.05 ± 74.46 | 1 (1.0-1.0) | 0.4 |
| WBC ($\times 10^3/\mu\text{L}$) | 9.31 ± 3.77 | 1.09 (1.08-1.1) | <0.0001 |
| LDL-cholesterol (mg/dL) | 109.2 ± 43.11 | 1 (1.0-1.0) | <0.0001 |
| HDL-cholesterol (mg/dL) | 37.05 ± 10.32 | 0.98 (0.98-0.99) | <0.0001 |
| Triglyceride (mg/dL) | 155 ± 111.97 | 1 (1.0-1.0) | 0.001 |
| Total cholesterol (mg/dL) | 176.47 ± 50.59 | 1 (0.99-1.0) | <0.0001 |

ACS – acute coronary syndrome; BMI – body mass index; CABG – coronary artery bypass graft; CCS – chronic coronary syndrome; CrCl – creatinine clearance; COPD – chronic obstructive pulmonary disease; CPR – cardiopulmonary resuscitation; CXA – circumflex artery; DES – drug eluting stent; HDL – high density lipoprotein; HR – hazard ratio; ICU – intensive care unit; LAD – left anterior descending artery; LBBB – left bundle branch block; LDL – low density lipoprotein; LM – left main artery; LVEF – left ventricular ejection fraction; MI – myocardial infarction; PCI – percutaneous coronary intervention; RCA – right coronary artery; TIMI – Thrombolysis In Myocardial Infarction; UA – unstable angina; WBC – white blood cells.

*Only for acute coronary syndromes.


Supplemental Figure 1 – Cumulative hazard plot and numbers at risk table for all-cause and cardiovascular cause mortality in a per patient and per PCI analysis.







| All-cause mortality | | | | | | | |
|---------------------|------|------|------|------|------|------|------|
| At risk | 6867 | 5496 | 4267 | 3353 | 2285 | 1269 | 206 |
| Censored | 0 | 671 | 1641 | 2317 | 3209 | 4122 | 5140 |
| Events | 0 | 700 | 959 | 1197 | 1373 | 1476 | 1521 |
| CV cause mortality | | | | | | | |
| At risk | 6867 | 5496 | 4267 | 3353 | 2285 | 1269 | 206 |
| Censored | 0 | 770 | 1817 | 2563 | 3503 | 4432 | 5450 |
| Events | 0 | 601 | 783 | 951 | 1079 | 1166 | 1211 |



| All-cause mortality | | | | | | | |
|---------------------|------|------|------|------|------|------|------|
| At risk | 8442 | 6863 | 5429 | 4392 | 3085 | 1676 | 260 |
| Censored | 0 | 824 | 1933 | 2675 | 3747 | 5025 | 6386 |
| Events | 0 | 755 | 1080 | 1375 | 1610 | 1741 | 1796 |
| CV cause mortality | | | | | | | |
| At risk | 8442 | 6863 | 5429 | 4392 | 3085 | 1676 | 260 |
| Censored | 0 | 933 | 2140 | 2976 | 4115 | 5418 | 6779 |
| Events | 0 | 646 | 873 | 1074 | 1242 | 1348 | 1403 |


Supplemental Figure 2 – Cumulative hazard plot and numbers at risk table for all-cause and cardiovascular cause mortality among investigated groups in a per-PCI analysis.





Supplemental Figure 3 – Cumulative hazard plot for all-cause and cardiovascular cause mortality stratified on presentation type.**(A) Per patient analysis****(B) Per PCI analysis**

Supplemental Figure 4 – Cumulative hazard plot for all-cause and cardiovascular cause mortality in acute coronary syndrome.**(C) Per patient analysis****(D) Per PCI analysis**

Supplemental Figure 5 – Cumulative hazard plot for all-cause and cardiovascular cause mortality in chronic coronary syndrome.**(A) Per patient analysis****(B) Per PCI analysis**

Supplemental Figure 6 – Observed mortality trends in all patients and among ethnic groups.

Supplemental Figure 7 – Hospitalization for chronic and acute coronary syndromes in the analyzed timeframe.

Supplemental Figure 8 – Guidelines recommended treatment prescription among ethnic groups.

ARNI – angiotensin receptor-neprilysin inhibitor; DOAC – direct oral anticoagulant; HF – heart failure; SGLT2 – sodium-glucose cotransporter 2; VKA – vitamin K antagonist. * Fully coverage by nationwide price-volume agreement was introduced. ** Half coverage by nationwide price-volume agreement was introduced.